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Abstract
Background: Rosiglitazone not only improves insulin-sensitivity, but also exerts anti-inflammatory
effects. We have now examined in type 2 diabetic patients if these effects are reflected by changes
in mRNA expression in peripheral blood mononuclear cells (PBMCs) to see if these cells can be
used to study these anti-inflammatory effects at the molecular level in vivo.
Method: Eleven obese type 2 diabetic patients received rosiglitazone (2 × 4 mg/d) for 8 weeks.
Fasting blood samples were obtained before and after treatment. Ten obese control subjects
served as reference group. The expression of NFκB-related genes and PPARγ target genes in
PBMCs, plasma TNFα, IL6, MCP1 and hsCRP concentrations were measured. In addition, blood
samples were obtained after a hyperinsulinemic-euglycemic clamp.
Results: Rosiglitazone reduced plasma MCP1 and hsCRP concentrations in diabetic patients (-9.5
± 5.3 pg/mL, p  = 0.043 and -1.1 ± 0.3 mg/L p  = 0.003), respectively). For hsCRP, the concentration
became comparable with the non-diabetic reference group. However, of the 84 NFκB-related
genes that were measured in PBMCs from type 2 diabetic subjects, only RELA, SLC20A1, INFγ and
IL1R1 changed significantly (p  < 0.05). In addition, PPARγ and its target genes (CD36 and LPL) did
not change. During the clamp, insulin reduced plasma MCP1 concentration in the diabetic and
reference groups (-9.1 ± 1.8%, p  = 0.001 and -11.1 ± 4.1%, p  = 0.023, respectively) and increased
IL6 concentration in the reference group only (23.5 ± 9.0%, p  = 0.028).
Conclusion:  In type 2 diabetic patients, the anti-inflammatory effect of rosiglitazone is not
reflected by changes in NFκB and PPARγ target genes in PBMCs in vivo. Furthermore, our results
do not support that high insulin concentrations contribute to the pro-inflammatory profile in type
2 diabetic patients.
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Background
Rosiglitazone, an agonist for the nuclear receptor peroxi-
some proliferator-activated receptor gamma (PPARγ), is a
widely used drug for the treatment of type 2 diabetes mel-
litus. It belongs to the group of thiazolidinediones (TZD)
and increases insulin sensitivity of peripheral tissues. In
addition, there is evidence that rosiglitazone has anti-
inflammatory effects [1-3]. It has been postulated that ros-
iglitazone exerts its anti-inflammatory effect through inhi-
bition of the transcription factor nuclear factor κB (NFκB)
pathway [1]. Normally, NFκB is bound in the cytosol to its
inhibitor κB (IκB) to prevent activation of NFκB. Inflam-
matory signals can cause phosphorylation of IκB, thereby
releasing and activating NFκB, followed by translocation
of NFκB to the nucleus and activation of genes involved in
the pro-inflammatory response, such as TNFα and matrix
metalloproteinases [4]. To further understand in humans
the in vivo  (anti-inflammatory) effects of rosiglitazone
treatment at the molecular level, it would be advanta-
geous that Peripheral Blood Mononuclear Cells (PBMCs)
could be used. These cells are readily accessible in humans
compared to the relatively inaccessible target tissues of
PPARγ ligands, namely adipose tissue and liver [5]. It has
already been demonstrated that monocytes respond to
PPARγ ligands by reducing the expression of inflamma-
tory cytokines ex vivo, such as TNFα, IL-6 and IL1b [6]. In
addition, Mohanty et al. [3] have shown that rosiglitazone
inhibits the binding of NFκB to DNA in the nucleus of
PBMCs from obese and obese diabetic patients. This was
accompanied by an anti-inflammatory effect, as indicated
by reduced plasma hsCRP and MCP-1 concentrations [3].
However, it is not known if rosiglitazone's anti-inflamma-
tory effect changes the transcription of NFκB related genes
in PBMCs in vivo. Therefore, the first aim of our study was
to examine if anti-inflammatory properties of rosiglita-
zone are reflected in changes in expression of genes
involved in the NFκB signaling pathway in PBMCs. Fur-
thermore, the role of an increased insulin concentration
in low-grade systemic inflammation, as often seen in type
2 diabetic patients, is not completely understood [7].
Therefore, the second aim of this study was to examine
plasma inflammatory markers in the fasted (hyperglycae-
mic) state and during hyperinsulinemia using a hyperin-
sulinemic-euglycemic clamp.
Methods
Subjects
Twelve middle-aged obese men with well-controlled type
2 diabetes mellitus participated in this study. Due to
extreme changes in serum cholesterol concentrations and
gene expression profiles, one subject was excluded from
the statistical analyses. The characteristics of the 11
remaining (age, 62 ± 5 y; body mass index (BMI), 31 ± 3
kg/m2) type 2 diabetic subjects and 10 BMI and age
matched normoglycemic controls (age, 57 ± 8 y; BMI, 30
± 4 kg/m2) are shown in table 1. Type 2 diabetes mellitus
was diagnosed at least 1 year before the study, and most
patients were treated with sulphonylurea (n = 3) or met-
formin (n = 5) or both (n = 1) as anti-diabetic medication.
Control subjects had normal glucose homeostasis, as
determined with a standard oral glucose tolerance test,
and had no family history of diabetes. The Medical Ethical
Review Board of Maastricht University had approved the
study and written, informed consent was obtained from
all volunteers.
Study design
Details of this study have been described previously [8,9].
In short, diabetic patients stopped any anti-diabetic med-
ication 14 days before the start of the study. Subjects were
asked not to participate in (exhaustive) physical activity
the last three days preceeding the measurements, and to
consume a diet according to the Dutch guidelines for a
healthy diet. After a baseline hyperinsulinemic-euglyc-
emic clamp, diabetic patients were treated with rosiglita-
zone (Avandia®, GlaxoSmithKline, Zeist, the
Table 1: BMI and plasma parameters of type 2 diabetic patients before and after rosiglitazone treatment and of non-diabetic controls.
Diabetic patients (n = 11) Controls (n = 10)
Before treatment After treatment
BMI (kg/m2) 30 ± 1.0 31 ± 1.0 31 ± 1.3
Glucose (mmol/L) 9.2 ± 0.5a 8.1 ± 0.5b,c 5.8 ± 0.1
Insulin (mU/L) 24.1± 3.1a 17.2 ± 1.7b,c 12.3 ± 0.9
GIR (μmol/kg/min) 12.8± 1.3a 20.6 ± 1.7b 24.6 ± 2.4
Total cholesterol (mmol/L) 5.4 ± 0.3 5.7 ± 0.4 5.2 ± 0.3
LDL cholesterol (mmol/L) 3.5 ± 0.2 3.8 ± 0.4 3.4 ± 0.3
HDL cholesterol (mmol/L) 0.93 ± 0.1 1.10± 0.1b 1.14 ± 0.1
TCH/HDL ratio 6.9 ± 1.1 5.5 ± 1.0 5.5 ± 1.1
Triglycerides (mmol/L) 2.0 ± 0.3 1.5 ± 0.2b 1.5 ± 0.4
FFA (mmol/L) 509 ± 47 400 ± 37b 513 ± 45.6
a Significantly different (P  < 0.05) between diabetic patients and non-diabetic controls
b Significant effect (P  < 0.05) of rosiglitazone treatment in diabetic patients
c Significantly different (P  < 0.05) between diabetic patients after rosiglitazone treatment and non-diabetic controlsBMC Endocrine Disorders 2009, 9:8 http://www.biomedcentral.com/1472-6823/9/8
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Netherlands), 8 mg/day (2 × 4 mg) for 8 weeks. After ros-
iglitazone treatment, subjects underwent a second clamp.
Blood samples were drawn before and after the clamp,
thereby providing fasting and insulin-stimulated blood
samples before and after rosiglitazone treatment.
The non-diabetic patients served as baseline controls to
the diabetic patients. They also underwent a hyperin-
sulinemic-euglycemic clamp, but were not treated with
rosiglitazone.
Hyperinsulinemic-euglycemic clamp
After an overnight fast, subjects came to the laboratory at
8 AM. A cannula was inserted into each antecubital vein
for the infusion of tracer, insulin and glucose. A third can-
nula was inserted retrogradely into a superficial dorsal
hand vein for arterialized blood sampling. After taking
fasting blood samples, a primed constant infusion of
[6,6]-2H2-glucose was initiated (0.04 mg/kg·min) for 300
minutes. At t = 120 min, a 3-hour primed constant infu-
sion of insulin (Actrapid, Novo Nordisk, Bagsvaerd, Den-
mark) was started (40 mU/m2·min), and glucose was
clamped by a variable co-infusion of 20% glucose with
tracer added. Blood samples taken at t = 0 min and t = 300
min were used for further analysis.
Plasma measurements
EDTA plasma was obtained by 10 minutes of centrifuga-
tion at 3000 rpm immediately after sampling, and stored
at -80°C for later analysis. Concentrations of total choles-
terol (ABX Diagnostics, Montpelier, France), HDL choles-
terol (precipitation method; Roche Diagnostics
Corporation, Indianapolis, IN), and triglycerides cor-
rected for free glycerol (Sigma-Aldrich Chemie, Stein-
heim, Germany) were analysed enzymatically. Serum LDL
cholesterol concentrations were calculated by using the
formula of Friedewald et al. [10]. Insulin concentrations
were measured using a RIA (Linco Research. St. Charles,
MO, USA). Free fatty acids (FFA) were determined using
the Wako Nefa C test kit (Wako Chemicals, Neuss, Ger-
many) and plasma glucose was determined by using the
hexokinase method (LaRoche, Basel, Switzerland). The
glucose infusion rate (GIR) was used as a measure of insu-
lin sensitivity. For the inflammation markers, high sensi-
tive CRP (hsCRP) was measured on Cobas Mira with a
commercial available kit (Kamiya Biomedical Company,
Seattle, WA, USA) and TNFα, IL6 and MCP1 were meas-
ured with an ELISA kit from R&D systems. All samples
from one subject were analysed in the same analytical run.
Samples were corrected for plasma albumin concentra-
tions to correct for changes in blood volume due to fluid
infusion during the hyperinsulinemic-euglycemic clamp
[11].
PBMC isolation and total RNA isolation
PBMCs were isolated from an EDTA anti-coagulated
peripheral fasted blood sample of diabetic patients only,
directly after blood sampling through gradient centrifuga-
tion using lymphoprep (Nycomed, Oslo, Norway)
according to the instructions from the manufacturer. The
obtained PBMCs were immediately lysed and homoge-
nised in 1.5 ml Trizol (Invitrogen Life Technologies,
Breda, The Netherlands) for RNA stabilisation and subse-
quent RNA isolation according a standardized protocol as
described by the manufacturer. Next, RNA was purified
using the RNeasy mini kit (Qiagen Benelux B.V., Venlo,
the Netherlands) followed by dissolving the RNA in
RNAse and DNAse free water (Invitrogen Life Technolo-
gies, Breda, The Netherlands). RNA purity was measured
on the NanoDrop 1000 (NanoDrop Technologies, Wilm-
ington, DE, USA), and considered suitable for further
processing at 260/280 and 260/230 ratios of > 1.7. Integ-
rity was evaluated using the BioAnalyzer (Agilent, Palo
Alto CA, USA) and considered to be intact with an RNA
integrity number > 7.0.
Real time PCR
cDNA was synthesised using the ReactionReady™ First
Strand cDNA Synthesis Kit (SuperArray Bioscience corpo-
ration, Frederick, MD, USA). The total amount of RNA
used in the reaction varied from 800 ng to 1 μg. Equal
amounts of RNA were used for samples before and after
treatment of the same subject.
Gene expression of NFκB pathway focussed genes was
analysed using NFκB RT2 Profiler  PCR arrays, according to
the manufacturer's instructions (SuperArray Bioscience
Corporation, Frederick, MD, USA). The PCR array con-
sisted of a 96-well plate including primer sets of 84 NFκB
related genes (see additional file 1), plus 5 housekeeping
genes and 2 negative controls. The primer sets were opti-
mised for real time detection using RT2 Real Time™ SYBR
Green PCR master mix (SuperArray Bioscience Corpora-
tion, Frederick, MD, USA). In addition, the relative expres-
sion levels of PPARγ, CD36 and LPL, were also
determined with real time PCR, using assays-on-demand
and Taqman Universal Mastermix (Applied Biosystems,
Foster City, CA, USA). All gene expression analyses were
performed on the ABI PISM 7000 system (Applied Biosys-
tems, Foster City, CA, USA).
Data analysis of real time PCR data
The No Template Control tested for DNA contamination
in the PCR system and the No Reverse Transcription Con-
trol tested for contamination of the original RNA with
genomic DNA. Those threshold cycles were above 35,
which indicates that there was no contamination. The
average Ct values of the housekeeping genes, β-actin and
18srRNA, were used for normalisation of each individualBMC Endocrine Disorders 2009, 9:8 http://www.biomedcentral.com/1472-6823/9/8
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sample. To express the difference in expression before and
after rosiglitazone treatment in diabetic patients, the ΔΔCt
value was calculated for each gene according to the com-
parative Ct method, and was used for statistical analysis.
Statistics
Fasting plasma parameters are presented as mean ± SEM.
Gene expression levels were not normally distributed and
are therefore expressed as median ΔΔCt values together
with corresponding ranges. An independent Student's t-
test was used to compare diabetic patients before or after
rosiglitazone with control subjects. Results of plasma
parameters before and after rosiglitazone treatment in
type 2 diabetic patients were analysed using a paired Stu-
dent's t-test. The effect of rosiglitazone on gene expression
levels in type 2 diabetic patients was analysed with the
non-parametric Wilcoxon signed rank test. Changes (%)
in plasma parameters during the hyperinsulinemic-eugly-
cemic clamp (T0 vs. T300) were tested with a one sample
t-test. In addition, using the Student's t-test, the changes in
plasma parameters induced by the hyperinsulinemic-eug-
lycemic clamp before rosiglitazone treatment were com-
pared to the clamp-induced changes after rosiglitazone
treatment.
All statistical analyses were performed with SPSS 14.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Body weight
There was no difference in body weight between diabetic
patients and the BMI-matched controls (94.3 ± 4.1 kg and
92.7 ± 4.1 kg, respectively (p  = 0.778)). Rosiglitazone
treatment resulted in a slight, but non-significant increase
in body weight during the 8 weeks follow-up period in the
diabetic patients (1.3 ± 1.0 kg, p  = 0.21).
Plasma glucose and insulin concentrations and insulin 
sensitivity
As expected, diabetic patients were less insulin-sensitive
and had higher fasting plasma glucose and insulin con-
centrations compared with non-diabetic controls (Table
1). Fasting glucose and insulin were significantly
decreased in the diabetic patients after rosiglitazone treat-
ment (-1.0 ± 0.5 mmol/L, p  = 0.044) and (-6.9 ± 2.3 mU/
L,  p   = 0.013, respectively), while insulin sensitivity
increased (change in GIR: +7.8 ± 1.9 μmol/kg/min, p  =
0.002) (Table 1).
Plasma lipid concentrations
As shown in Table 1, there were no significant differences
in plasma total cholesterol, LDL cholesterol, HDL choles-
terol, TCH/HDL ratio, triglycerides and free fatty acids
(FFA) between diabetic patients and non-diabetic con-
trols. Fasting HDL cholesterol increased significantly
(+0.21 ± 0.07 mmol/L, p  = 0.013), while triglyceride and
FFA concentrations decreased (-0.48 ± 0.21 mmol/L, p  =
0.042 and -109 ± 38 mmol/L, p  = 0.018 respectively)
upon rosiglitazone treatment in diabetic patients. Total
cholesterol and LDL cholesterol concentrations were not
significantly affected by rosiglitazone treatment (+0.30 ±
0.20 mmol/L, p  = 0.152 and +0.30 ± 0.20 mmol/L, p  =
0.160, respectively). The TCH/HDL ratio tended to
improve after treatment (-1.3 ± 0.7), but this did not reach
statistically significance (p  = 0.09).
Plasma hsCRP, TNFα, IL6 and MCP1 concentrations
As shown in figure 1, the basal plasma concentration of
hsCRP in the diabetic patients was 2.2 ± 0.4 mg/L, which
was significantly higher than that of the non-diabetic con-
trols (1.0 ± 0.2 mg/L, p  = 0.027). There were no differ-
ences in TNFα, IL6 and MCP1 concentrations between
diabetic patients and control subjects. As a result of rosigl-
itazone treatment, basal hsCRP and MCP1 concentrations
significantly decreased (-1.1 ± 0.3 mg/L, p  = 0.003 and -
9.5 ± 5.3 pg/mL, p  = 0.043, respectively) and, paradoxi-
cally, TNFα concentrations increased (+0.22 ± 0.1 pg/mL,
p  = 0.037) in type 2 diabetic patients. After rosiglitazone
treatment, hsCRP (1.0 ± 0.16 mg/L) and MCP1 concentra-
tions (132 ± 7 pg/mL) in diabetic patients were compara-
ble with those measured in non-diabetic controls.
Expression of PPARγ, PPARγ responsive genes and NFκB 
related genes
Of the 84 genes measured, 75 were detectable in PBMCs
and only the expression of genes encoding for IFNγ (inter-
feron gamma), IL1R1 (interleukin 1 receptor 1), RELB (V-
rel reticuloendotheliosis viral oncogene homolog B,
nuclear factor of kappa light polypeptide gene enhancer in
B-cells 3 (avian)) and SLC20A1 (solute carrier family 20
(phosphate transporter) member 1) changed significantly
in the diabetic patients upon rosiglitazone treatment
(table 2).
The expression level of PPARγ itself was not changed by its
ligand rosiglitazone. Also expression levels of CD36
(thrombospondin receptor) and LPL (lipoprotein lipase),
which are known PPARγ target genes [12-14], did not
change (Table 2).
Changes in plasma parameters during the clamp
Before rosiglitazone treatment, plasma albumin concen-
trations were 38.1 ± 0.6 g/L before the clamp and 36.8 ±
0.5 g/L after the clamp (p  = 0.005). These concentrations
were comparable after rosiglitazone treatment. For the
control subjects, these values were before and after the
clamp respectively 38.7 ± 0.6 g/L and 36.4 ± 0.7 g/L (p  <
0.001). The observed reductions in plasma albumin con-
centration indicate that due to the glucose infusion, the
plasma volume had changed during the clamp. Therefore,BMC Endocrine Disorders 2009, 9:8 http://www.biomedcentral.com/1472-6823/9/8
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levels of the plasma parameters were related to those of
albumin. It is known that plasma albumin concentrations
are stable during the day [11].
Before treatment, serum total, LDL, and HDL cholesterol
levels did not change in response to insulin during the
hyperinsulinemic-euglycemic clamp in both type 2 dia-
betic patients and control subjects (Table 3). Triglycerides
levels decreased in control subjects (-16.7 ± 4,5%, p  =
0.007) and also in diabetic patients after rosiglitazone
treatment (-14.3 ± 5.5%, p  = 0.027). FFA levels decreased
significantly in type 2 diabetic patients (-58.9 ± 3.4%, p  <
0.001) in response to insulin. In control subjects the
reduction in FFA was even more pronounced (-80.1 ±
2.6%, p  < 0.001). Rosiglitazone improved the insulin-
induced decrease in FFA (from -58.9 ± 3.4% to -65.0 ±
4.1%, p  = 0.045).
Insulin significantly decreased MCP1 levels in type 2 dia-
betic patients before rosiglitazone treatment (-9.1 ± 1.8%,
p  = 0.001) and control subjects (-11.1 ± 4.1%, p  = 0.023)
(table 3). Control subjects also showed a significant
increase in IL6 levels (23.5 ± 9.0%, p  = 0.028) Changes in
TNFα levels upon insulin stimulation differed signifi-
cantly before and after rosiglitazone treatment in diabetic
patients. Levels of TNFα increased during the clamp
before rosiglitazone treatment (+12.0 ± 6.6%), but
decreased after rosiglitazone treatment (-9.1 ± 7.9%, p  =
0.006).
Discussion
In this study, 8 weeks of rosiglitazone treatment (2 × 4
mg/d) not only improved insulin sensitivity and plasma
lipids, but also lowered fasting plasma concentrations of
hsCRP and MCP1. After rosiglitazone, fasting concentra-
Concentrations of plasma inflammation markers in controls and in diabetics before and after rosiglitazone treatment Figure 1
Concentrations of plasma inflammation markers in controls and in diabetics before and after rosiglitazone 
treatment. Baseline concentrations of plasma inflammatory markers, A) hsCRP, B) TNFα, C) IL6 and D) MCP1, in type 2 dia-
betic and control subjects and levels after rosiglitazone treatment in type 2 diabetic patients. * = p-value < 0.05.BMC Endocrine Disorders 2009, 9:8 http://www.biomedcentral.com/1472-6823/9/8
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tions of hsCRP and MCP1 in diabetic patients were even
comparable to those of non-diabetic controls. These anti-
inflammatory changes were not reflected in the expression
of NFκB-related genes in PBMCs.
Reductions in fasting triglyceride concentrations have
been reported for other TZDs, such as pioglitazone, trogl-
itazone and darglitazone. We have now shown that these
results can be extended to rosiglitazone. Furthermore, FFA
concentrations were also reduced after rosiglitazone treat-
ment. These reductions may be explained by an increased
clearance of TG and FFA, as shown by Dhindsa et al. [15].
Rosiglitazone treatment further significantly increased
serum HDL cholesterol concentrations and total choles-
terol and LDL cholesterol tended to increase Generally,
the effects of rosiglitazone on serum lipid concentrations
were comparable to those of other TZDs [16].
Rosiglitazone treatment in type 2 diabetic patients
decreased hsCRP and MCP1 concentrations, indicating a
reduced inflammatory state. Mohanty et al. also observed
a significant reduction in MCP1 and hsCRP concentra-
tions after 6 weeks of rosiglitazone treatment (4 mg/d) in
non-diabetic obese subjects and obese diabetic patients
[3]. In accordance with previous studies [2,17,18], we did
not observe an effect of rosiglitazone on plasma IL6 con-
centrations. The increase we observed in TNFα concentra-
tions is unexpected, although studies on the effects of
TZDs on plasma TNFα concentrations are inconsistent.
Some studies have shown that plasma concentrations of
this cytokine are increased in subjects with insulin resist-
ance or type 2 diabetes [19,20]. A number of other studies,
however, showed reduced TNFα concentrations [21,22]
after rosiglitazone treatment in type 2 diabetic patients,
whereas others found no effect [18]. In line with our
observations, Goldstein et al. [23] showed that TNFα con-
centrations were significantly increased when rosiglita-
zone was added to metformin treatment in type 2 diabetic
patients. Due to these inconsistent results, a clear explana-
tion is lacking.
Despite the rosiglitazone-induced reductions in fasting
plasma CRP and MCP1, which are under control of NFκB
[24,25], expression of NFκB-related genes in PBMCs
hardly changed upon rosiglitazone treatment. Of the 75
detectable NFκB-related genes in PBMCs, only 4 genes
were significantly altered. The gene encoding for inter-
feron gamma (INFγ) was significantly upregulated,
whereas ILR1, RELB and SLC20A1 were significantly
downregulated by rosiglitazone treatment. These changes
would indicate an inhibition of the NFκB signalling cas-
Table 2: Effect of rosiglitazone treatment on expression levels 
(ΔCt) of PPARγ, PPARγ responsive genes and NFκB related 
genes in type 2 diabetic patients1,2
Gene ΔΔCt (after – before treatment) p-value3
PPARγ 0.31 (-0.70 – 1.29) 0.213
CD36 0.37 (-0.93 – 0.90) 0.248
LPL -0.39 (-0.90 – 1.26) 0.248
INFγ -0.53 (-3.04 – 0.62) 0.045
IL1R1 0.37 (-1.16 – 1.51) 0.041
RELB 0.31 (-0.23 – 2.27) 0.016
SLC20A1 0.41 (-1.03 – 1.93) 0.033
1 The expression of 84 genes related to NFκB was profiles using the 
RT2Profiler™ PCR Array; n = 11
2 Values are reported as ΔΔCt values and presented as medians with 
ranges. A negative ΔΔCt value corresponds with an upregulation and a 
positive ΔΔCt value with a downregulation of the gene after 
rosiglitazone treatment.
3 Gene expression levels (ΔCt values) were analysed with the non-
parametric Wilcoxon signed rank test. Differences were considered 
significant at a p-value < 0.05
Table 3: Relative changes in plasma parameters upon insulin-stimulation during the hyperinsulinemic-euglycemic clamp
Diabetic patients (n = 11) Controls (n = 10)
Before treatment After treatment
Albumin (%) -3.4 ± 0.9# -3.1 ± 1.1# -6.0 ± 0.8#
Total cholesterol (%) 0.4 ± 0.8 -1.7 ± 1.4 0.4 ± 0.7
LDL cholesterol (%) 2.5 ± 2.1 -0.5 ± 1.3 2.3 ± 1.1
HDL cholesterol (%) 1.3 ± 2.7 0.8 ± 1.6 2.7 ± 1.3
Triglycerides (%) -5.2 ± 6.4 -14.3 ± 5.5a,c -16.7 ± 4.5a
FFA (%) -58.9 ± 3.4a,b -65.0 ± 4.1a,c -80.1 ± 2.6a
hsCRP (%) -4.7 ± 2.7 -4.9 ± 2.4 5.5 ± 4.5
TNFα (%) 12.0 ± 6.6 -9.1 ± 7.9c 12.1 ± 14.2
IL6 (%) 13.7 ± 6.7 16.4 ± 7.9 23.5 ± 9.0a
MCP1 (%) -9.1 ± 1.8a -3.7 ± 4.0 -11.1 ± 4.1a
# Plasma albumin changed (p < 0.05) during the clamp because of increase in blood volume due to fluid infusion. Therefore, all plasma parameters 
are corrected for changes in plasma albumin concentration and presented as mean ± SEM
a Significant change (P  < 0.05) in response to insulin
b Significant difference between type 2 diabetic patients and BMI-matched controls in response to insulin
c Significant change (P  < 0.05) effect of rosiglitazone treatment on the response to insulin in type 2 diabetic patientsBMC Endocrine Disorders 2009, 9:8 http://www.biomedcentral.com/1472-6823/9/8
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cade [4,26-28]. The significant reduction in MCP1 and
hsCRP concentrations after 6 weeks of rosiglitazone treat-
ment (4 mg/d) in non-diabetic obese subjects and obese
diabetic patients as described by Mohanty et al., was
accompanied by a significant fall in intranuclear NFκB
levels in PBMCs [3]. This suggests a direct interference of
PPARγ in the binding of NFκB to the promotor regions of
proinflammatory genes. However, these reduced intranu-
clear NFκB levels were not accompanied by a changed
expression of the NFκB-related genes IkB and p65 (REL A)
after rosiglitazone treatment [3,29]. For troglitazone,
another PPARγ agonist, it has also been demonstrated that
intranuclear and cellular levels of NFκB were decreased in
mononuclear cells of obese subjects [30]. Unfortunately,
these studies did not examine if the fall in intranuclear
NFκB levels was accompanied by a reduced expression of
inflammatory NFκB target genes. In our study, the lack of
effect on NFκB related genes by rosiglitazone in PBMCs
suggests that PBMCs are insensitive to rosiglitazone.
To further substantiate whether PBMCs were non-respon-
sive to rosiglitazone treatment, we evaluated if rosiglita-
zone influenced gene expression of specific PPARγ
dependent genes in PBMCs in vivo, i.e., PPARγ itself, CD36
and lipoprotein lipase (LPL). In vitro  and ex vivo  studies
have shown that expression of CD36 [31,32] and LPL [33]
in macrophages increased after activation of PPARγ. In our
study, however, the in vivo  expression of PPARγ, CD36
and LPL in PBMCs was not altered by rosiglitazone treat-
ment, which suggests that PBMCs are non-responsive to
rosiglitazone. In contrast to most other studies, we used
PBMCs, a mixed population of white blood cells, and
studied the in vivo  effects. Most studies that did observe
anti-inflammatory effects of rosiglitazone focussed on in
vitro  effects in a specific subpopulation of blood cells,
namely monocytes or macrophages. These studies showed
an increased expression of PPARγ and PPARγ responsive
genes when these cells were cultured ex vivo  or in vitro,
and/or were given extra cytokine stimulation [31,34,35].
In vivo, Bouhlel et al. [34] showed a significant upregula-
tion of PPARγ expression in PBMCs of subjects after 2
months of 45 mg/day pioglitazone (TZD) treatment in
patients with severe atherosclerosis, although expression
of the PPARγ dependent genes, CD136 and mannose
receptor, did not change. Combining these finding with
our results suggests that gene expression profiles in
PBMCs are not suitable to use as a biomarker to study in
vivo  the effects of rosiglitazone intervention at a molecu-
lar level. Whether specific subpopulations of cells within
PBMCs are suitable, warrant further investigation. In this
respect, study of monocytes, preferably isolated from
blood via for example cell sorter techniques, warrants
attention as especially the monocytes play an important
role in the inflammation process and insulin resistance.
Arkan et al. [36], for example, showed that deletion of
IKKβ, required for the activation of NFκB, in myeloid pre-
cursor cells protected animals from diet-induced obesity-
related insulin resistance.
To investigate the acute effect of insulin on the low-grade
pro-inflammatory profile in type 2 diabetic patients at
constant glucose concentrations, plasma inflammation
parameters were analysed before and after the hyperin-
sulinemic-euglycemic clamp. Results, however, were not
conclusive. MCP1 level decreased in both diabetic and
control subjects, IL6 level increased only in control sub-
jects, while hsCRP and TNFα levels did not significantly
change. The reduced MCP1 level after insulin stimulation
can, however, also be an indirect effect of insulin and
explained for example by the insulin-mediated reduction
in FFA [37]. The causal role of IL6 in the development of
insulin resistance and type 2 diabetes is not clear. Infusion
with a physiological concentration of IL6 in humans
increased the uptake of glucose in subcutaneous adipose
tissue  in vivo [38]. On the other hand, IL6 levels are
increased in type 2 diabetic subjects. Like in our study,
Krogh-Madsen et al. found an increase in plasma IL6 con-
centrations during a hyperinsulinemic-euglycemic clamp
in healthy human males [39]. This increase was accompa-
nied by an elevated insulin-stimulated increase in IL6
gene expression in adipose tissue. Also, they found no
change in plasma concentrations of TNFα, which expres-
sion was increased in adipose tissue and reduced in mus-
cle tissue [39]. The reason that we did not find a reduction
in hsCRP concentration may have been due to the relative
short time of insulin infusion in our study, as previous
studies demonstrated decreased hsCRP concentrations
after 10 or more hours of insulin infusion [40-42]. It also
needs to be mentioned that during the hyperinsulinemic-
euglycemic clamp, not only insulin infusion can exerts
biological effects, but also the amount of glucose infused
to maintain euglycemia [43]. However, Dandona et al.
have demonstrated an acute anti-inflammatory effect of
insulin infusion at a physiological concentration, infusing
insulin (2.0–2.5 IU/h) – dextrose(5%) and in obese non-
diabetic subjects, while maintaining glucose levels as
close to basal levels as possible [41]. This anti-inflamma-
tory effect was reflected by reduced intranuclear levels of
NFκB, increased IκB, decreased ROS generation and
decreased p47phox subunit in PBMCs, decreased plasma
intracellular adhesion molecule 1, plasminogen inhibitor
1 and MCP1 concentrations [41]. Infusion with only dex-
trose or saline had no effects on these parameters [41].
Taken together, a supra-physiological increase in insulin
concentration does not per se contribute to the distur-
bances in inflammatory markers in type 2 diabetic
patients.BMC Endocrine Disorders 2009, 9:8 http://www.biomedcentral.com/1472-6823/9/8
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Conclusion
In conclusion, 8 weeks of rosiglitazone treatment (2 × 4
mg/d) resulted in improved insulin sensitivity and lipid
profile and reduced concentrations of plasma inflamma-
tory markers (MCP1 and hsCRP) in type 2 diabetic
patients. Furthermore, plasma inflammatory parameters
did not change consistently during the clamp in both dia-
betic and control patients, which does not suggest that
high insulin levels contribute to the proinflammatory
state in type 2 diabetic patients. Finally, the anti-inflam-
matory effect of rosiglitazone is not reflected by changes
in NFκB and PPARγ target genes in PBMCs in vivo.
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